Research programme: anticancer radiotherapeutics - Algeta/Sanofi

Drug Profile

Research programme: anticancer radiotherapeutics - Algeta/Sanofi

Alternative Names: TTCs - Algeta/Sanofi; Tumour targeting conjugates - Algeta/Sanofi

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Algeta; Sanofi
  • Class Antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in Norway
  • 06 Mar 2014 Algeta has been acquired by Bayer
  • 30 Apr 2012 Algeta and Sanofi agree to extend their research collaboration for a further year
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top